159 related articles for article (PubMed ID: 37715360)
21. Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides.
Kaneda-Nakashima K; Shirakami Y; Kadonaga Y; Watabe T; Ooe K; Yin X; Haba H; Shirasaki K; Kikunaga H; Tsukada K; Toyoshima A; Cardinale J; Giesel FL; Fukase K
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256007
[TBL] [Abstract][Full Text] [Related]
22. Actinium-225 in targeted alpha-particle therapeutic applications.
Scheinberg DA; McDevitt MR
Curr Radiopharm; 2011 Oct; 4(4):306-20. PubMed ID: 22202153
[TBL] [Abstract][Full Text] [Related]
23. Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review.
Mdanda S; Ngema LM; Mdlophane A; Sathekge MM; Zeevaart JR
Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376167
[TBL] [Abstract][Full Text] [Related]
24. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing
Rathke H; Kratochwil C; Hohenberger R; Giesel FL; Bruchertseifer F; Flechsig P; Morgenstern A; Hein M; Plinkert P; Haberkorn U; Bulut OC
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):139-147. PubMed ID: 30151743
[TBL] [Abstract][Full Text] [Related]
25. Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists.
Shi M; Jakobsson V; Greifenstein L; Khong PL; Chen X; Baum RP; Zhang J
Front Med (Lausanne); 2022; 9():1034315. PubMed ID: 36569154
[TBL] [Abstract][Full Text] [Related]
26.
Sathekge M; Bruchertseifer F; Knoesen O; Reyneke F; Lawal I; Lengana T; Davis C; Mahapane J; Corbett C; Vorster M; Morgenstern A
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):129-138. PubMed ID: 30232539
[TBL] [Abstract][Full Text] [Related]
27. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
[TBL] [Abstract][Full Text] [Related]
28. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
29. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with
Kratochwil C; Bruchertseifer F; Rathke H; Hohenfellner M; Giesel FL; Haberkorn U; Morgenstern A
J Nucl Med; 2018 May; 59(5):795-802. PubMed ID: 29326358
[TBL] [Abstract][Full Text] [Related]
30. Alpha and Beta Radiation for Theragnostics.
Song H; Sgouros G
PET Clin; 2024 Jul; 19(3):307-323. PubMed ID: 38688775
[TBL] [Abstract][Full Text] [Related]
31.
Królicki L; Kunikowska J; Bruchertseifer F; Koziara H; Królicki B; Jakuciński M; Pawlak D; Rola R; Morgenstern A; Rosiak E; Merlo A
Semin Nucl Med; 2020 Mar; 50(2):141-151. PubMed ID: 32172799
[TBL] [Abstract][Full Text] [Related]
32. Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literature.
Stangl-Kremser J; Ricaurte-Fajardo A; Subramanian K; Osborne JR; Sun M; Tagawa ST; Bander NH
Prostate; 2023 Jul; 83(10):901-911. PubMed ID: 36960580
[TBL] [Abstract][Full Text] [Related]
33. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
34. DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy.
Graf F; Fahrer J; Maus S; Morgenstern A; Bruchertseifer F; Venkatachalam S; Fottner C; Weber MM; Huelsenbeck J; Schreckenberger M; Kaina B; Miederer M
PLoS One; 2014; 9(2):e88239. PubMed ID: 24516620
[TBL] [Abstract][Full Text] [Related]
35. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.
Kozempel J; Mokhodoeva O; Vlk M
Molecules; 2018 Mar; 23(3):. PubMed ID: 29510568
[TBL] [Abstract][Full Text] [Related]
36. Assessment of the radiation absorbed dose produced by
Azorín-Vega E; Rojas-Calderón E; Ferro-Flores G; Aranda-Lara L; Jiménez-Mancilla N; Nava-Cabrera MA
Appl Radiat Isot; 2019 Apr; 146():66-71. PubMed ID: 30753987
[TBL] [Abstract][Full Text] [Related]
37. A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro.
Nayak T; Norenberg J; Anderson T; Atcher R
Cancer Biother Radiopharm; 2005 Feb; 20(1):52-7. PubMed ID: 15778581
[TBL] [Abstract][Full Text] [Related]
38. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.
Alati S; Singh R; Pomper MG; Rowe SP; Banerjee SR
Semin Nucl Med; 2023 Sep; 53(5):663-686. PubMed ID: 37468417
[TBL] [Abstract][Full Text] [Related]
39. First Clinical Results for PSMA-Targeted α-Therapy Using
Zacherl MJ; Gildehaus FJ; Mittlmeier L; Böning G; Gosewisch A; Wenter V; Unterrainer M; Schmidt-Hegemann N; Belka C; Kretschmer A; Casuscelli J; Stief CG; Unterrainer M; Bartenstein P; Todica A; Ilhan H
J Nucl Med; 2021 May; 62(5):669-674. PubMed ID: 33008928
[TBL] [Abstract][Full Text] [Related]
40. An Overview of Targeted Alpha Therapy with
Morgenstern A; Apostolidis C; Kratochwil C; Sathekge M; Krolicki L; Bruchertseifer F
Curr Radiopharm; 2018; 11(3):200-208. PubMed ID: 29732998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]